These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 8519488)

  • 21. Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis.
    Molica S; Mannella A; Dattilo A; Levato D; Iuliano F; Peta A; Consarino C; Magro S
    Haematologica; 1996; 81(4):302-9. PubMed ID: 8870373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
    Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
    Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
    Belkacemi L; Lam E; Caldwell JD; Siemens DR; Graham CH
    Exp Cell Res; 2006 Jun; 312(10):1685-92. PubMed ID: 16564525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
    J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
    Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
    Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
    Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
    Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
    Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
    Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry.
    Rezaei A; Adib M; Mokarian F; Tebianian M; Nassiri R
    Med Sci Monit; 2003 Aug; 9(8):CR359-62. PubMed ID: 12942032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells.
    Berdel WE; Kulimova E; Kolkmeyer A; Zühlsdorf M; Serve H; Büchner T; Oelmann E
    Ann Hematol; 2005 Nov; 84(12):771-3. PubMed ID: 16094532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
    Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
    Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
    Reuning U; Magdolen V; Hapke S; Schmitt M
    Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
    Allgayer H; Heiss MM; Riesenberg R; Grützner KU; Tarabichi A; Babic R; Schildberg FW
    Cancer Res; 1997 Apr; 57(7):1394-9. PubMed ID: 9102229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
    Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
    Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.
    Béné MC; Castoldi G; Knapp W; Rigolin GM; Escribano L; Lemez P; Ludwig WD; Matutes E; Orfao A; Lanza F; van't Veer M;
    Leukemia; 2004 Mar; 18(3):394-400. PubMed ID: 14671631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
    Ramage JG; Vallera DA; Black JH; Aplan PD; Kees UR; Frankel AE
    Leuk Res; 2003 Jan; 27(1):79-84. PubMed ID: 12479856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein.
    Frankel AE; Beran M; Hogge DE; Powell BL; Thorburn A; Chen YQ; Vallera DA
    Exp Hematol; 2002 Nov; 30(11):1316-23. PubMed ID: 12423685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.